Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 10;9(11):3620.
doi: 10.3390/jcm9113620.

The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy

Patricia P Bloom  1 , Elliot B Tapper  1   2
Affiliations
Review

The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy

Patricia P Bloom et al. J Clin Med. .

Abstract

Hepatic encephalopathy (HE) is a devastating complication of cirrhosis with an increasing footprint in global public health. Although the condition is defined using a careful history and examination, we cannot accurately measure the true impact of HE relying on data collected exclusively from clinical studies. For this reason, administrative data sources are necessary to study the population burden of HE. Administrative data is generated with each health care encounter to account for health care resource utilization and is extracted into a dataset for the secondary purpose of research. In order to utilize such data for valid analysis, several pitfalls must be avoided-specifically, selecting the particular database capable of meeting the needs of the study's aims, paying careful attention to the limits of each given database, and ensuring validity of case definition for HE specific to the dataset. In this review, we summarize the types of data available for and the results of administrative data studies of HE.

Keywords: cirrhosis; epidemiology; liver disease.

PubMed Disclaimer

Conflict of interest statement

E.B.T. has served as a consultant to Norvartis, Axcella, and Allergan; has served on advisory boards for Mallinckrodt, Bausch Health, Kaleido, Novo Nordisk; and has received unrestricted research grants from Gilead and Valeant. P.P.B. serves as a consultant for Synlogic.

References

    1. Beste L.A., Leipertz S.L., Green P.K., Dominitz J.A., Ross D., Ioannou G.N. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149:1471–1482. doi: 10.1053/j.gastro.2015.07.056. - DOI - PubMed
    1. Tapper E.B., Parikh N.D. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: Observational study. BMJ. 2018;362:k2817. doi: 10.1136/bmj.k2817. - DOI - PMC - PubMed
    1. Tapper E.B., Halbert B., Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: A multistate population-based cohort study. Clin. Gastroenterol. Hepatol. 2016;14:1181–1188. doi: 10.1016/j.cgh.2016.04.009. - DOI - PubMed
    1. Tapper E.B., Kanwal F., Asrani S.K., Ho C., Ovchinsky N., Poterucha J., Flores A., Smith J.E., Ankoma-Sey V., Luxon B., et al. Patient reported outcomes in cirrhosis: A scoping review of the literature. Hepatology. 2017;67:2375–2383. doi: 10.1002/hep.29756. - DOI - PubMed
    1. Jepsen P., Ott P., Andersen P.K., Sørensen H.T., Vilstrup H. Clinical course of alcoholic liver cirrhosis: A Danish population-based cohort study. Hepatology. 2009;51:1675–1682. doi: 10.1002/hep.23500. - DOI - PubMed

LinkOut - more resources